Stock Track | Amphastar Pharmaceuticals Plunges 16.73% After-Hours on Q1 Earnings Miss, Lower Prices and Higher Costs

Stock Track05:36

Amphastar Pharmaceuticals' stock experienced a significant after-hours plunge of 16.73% following the release of its first-quarter financial results.

The company reported quarterly results that fell short of analyst expectations. Revenue was essentially flat year-over-year at $171.2 million, missing the consensus estimate. More notably, adjusted earnings per share came in at $0.42, significantly below the estimated $0.70 to $0.71, while GAAP net income plummeted 75% to $6.4 million.

The disappointing performance was driven by lower average selling prices for key products including BAQSIMI, glucagon, phytonadione, and epinephrine, which reduced gross margin. Additionally, higher manufacturing expenses from facility expansion and increased research & development costs, including a $2 million licensing payment, further pressured profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139445951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139445951","market":"nz","top_or_hot":-1,"title":"Stock Track | Amphastar Pharmaceuticals Plunges 16.73% After-Hours on Q1 Earnings Miss, Lower Prices and Higher Costs","media":"Stock Track","content":"<p>Amphastar Pharmaceuticals' stock experienced a significant after-hours plunge of 16.73% following the release of its first-quarter financial results.</p><p>The company reported quarterly results that fell short of analyst expectations. Revenue was essentially flat year-over-year at $171.2 million, missing the consensus estimate. More notably, adjusted earnings per share came in at $0.42, significantly below the estimated $0.70 to $0.71, while GAAP net income plummeted 75% to $6.4 million.</p><p>The disappointing performance was driven by lower average selling prices for key products including BAQSIMI, glucagon, phytonadione, and epinephrine, which reduced gross margin. Additionally, higher manufacturing expenses from facility expansion and increased research & development costs, including a $2 million licensing payment, further pressured profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amphastar Pharmaceuticals Plunges 16.73% After-Hours on Q1 Earnings Miss, Lower Prices and Higher Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amphastar Pharmaceuticals Plunges 16.73% After-Hours on Q1 Earnings Miss, Lower Prices and Higher Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amphastar Pharmaceuticals' stock experienced a significant after-hours plunge of 16.73% following the release of its first-quarter financial results.</p><p>The company reported quarterly results that fell short of analyst expectations. Revenue was essentially flat year-over-year at $171.2 million, missing the consensus estimate. More notably, adjusted earnings per share came in at $0.42, significantly below the estimated $0.70 to $0.71, while GAAP net income plummeted 75% to $6.4 million.</p><p>The disappointing performance was driven by lower average selling prices for key products including BAQSIMI, glucagon, phytonadione, and epinephrine, which reduced gross margin. Additionally, higher manufacturing expenses from facility expansion and increased research & development costs, including a $2 million licensing payment, further pressured profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"","article_id":"1139445951","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139445951","pubTimestamp":1778189787,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amphastar Pharmaceuticals' stock experienced a significant after-hours plunge of 16.73% following the release of its first-quarter financial results.The company reported quarterly results that fell...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"个股追踪|Amphastar Pharmaceuticals盘后暴跌16.73%因Q1盈利不及、价格下跌和成本上升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"Amphastar Pharmaceuticals' stock experienced a significant after-hours plunge of 16.73% following the release of its first-quarter financial results.The company reported quarterly results that fell short of analyst expectations. Revenue was essentially flat year-over-year at $171.2 million, missing the consensus estimate. More notably, adjusted earnings per share came in at $0.42, significantly below the estimated $0.70 to $0.71, while GAAP net income plummeted 75% to $6.4 million.The disappointing performance was driven by lower average selling prices for key products including BAQSIMI, glucagon, phytonadione, and epinephrine, which reduced gross margin. Additionally, higher manufacturing expenses from facility expansion and increased research & development costs, including a $2 million licensing payment, further pressured profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139445951","isCrawlerRequest":true}